We found that in luminal and HER2 amplified breast cell lines and tumors, CREB3L1 mRNA expression was frequently increased, whereas in TNBC cell lines and tumor samples, CREB3L1 expression was frequently low. This evidence concerns the gene ERBB2 and neoplasm.